Mason Carrico
Stock Analyst at Stephens & Co.
(2.88)
# 1,726
Out of 4,735 analysts
58
Total ratings
40%
Success rate
0.76%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MYGN Myriad Genetics | Reiterates: Equal-Weight | $20 | $12.57 | +59.11% | 4 | Jan 16, 2025 | |
| VCEL Vericel | Reiterates: Overweight | $65 | $59.56 | +9.13% | 1 | Jan 15, 2025 | |
| CSTL Castle Biosciences | Reiterates: Overweight | $41 | $26.72 | +53.44% | 7 | Jan 2, 2025 | |
| ILMN Illumina | Maintains: Overweight | $170 → $184 | $141.31 | +30.21% | 6 | Nov 12, 2024 | |
| TXG 10x Genomics | Reiterates: Overweight | $30 | $16.16 | +85.64% | 5 | Oct 10, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Overweight | $3.5 → $2.5 | $1.70 | +47.06% | 2 | Aug 13, 2024 | |
| NTRA Natera | Reiterates: Overweight | $125 | $167.46 | -25.36% | 4 | Aug 9, 2024 | |
| HOLX Hologic | Reiterates: Overweight | $92 | $70.37 | +30.74% | 2 | Jul 30, 2024 | |
| NEO NeoGenomics | Reiterates: Overweight | $19 | $14.18 | +33.99% | 1 | Jul 30, 2024 | |
| GH Guardant Health | Reiterates: Overweight | $44 | $45.13 | -2.50% | 4 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $18 | $22.70 | -20.70% | 8 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $4 | $2.12 | +88.68% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $5.88 | +53.06% | 1 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $9 | $3.02 | +198.01% | 4 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $43.60 | -22.02% | 6 | Oct 10, 2023 |
Myriad Genetics
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $12.57
Upside: +59.11%
Vericel
Jan 15, 2025
Reiterates: Overweight
Price Target: $65
Current: $59.56
Upside: +9.13%
Castle Biosciences
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $26.72
Upside: +53.44%
Illumina
Nov 12, 2024
Maintains: Overweight
Price Target: $170 → $184
Current: $141.31
Upside: +30.21%
10x Genomics
Oct 10, 2024
Reiterates: Overweight
Price Target: $30
Current: $16.16
Upside: +85.64%
Pacific Biosciences of California
Aug 13, 2024
Maintains: Overweight
Price Target: $3.5 → $2.5
Current: $1.70
Upside: +47.06%
Natera
Aug 9, 2024
Reiterates: Overweight
Price Target: $125
Current: $167.46
Upside: -25.36%
Hologic
Jul 30, 2024
Reiterates: Overweight
Price Target: $92
Current: $70.37
Upside: +30.74%
NeoGenomics
Jul 30, 2024
Reiterates: Overweight
Price Target: $19
Current: $14.18
Upside: +33.99%
Guardant Health
May 24, 2024
Reiterates: Overweight
Price Target: $44
Current: $45.13
Upside: -2.50%
May 13, 2024
Maintains: Overweight
Price Target: $15 → $18
Current: $22.70
Upside: -20.70%
Apr 17, 2024
Reiterates: Equal-Weight
Price Target: $4
Current: $2.12
Upside: +88.68%
Dec 14, 2023
Initiates: Overweight
Price Target: $9
Current: $5.88
Upside: +53.06%
Nov 13, 2023
Maintains: Overweight
Price Target: $14 → $9
Current: $3.02
Upside: +198.01%
Oct 10, 2023
Reiterates: Overweight
Price Target: $34
Current: $43.60
Upside: -22.02%